I have previously posted articles relating to Neuren Pharmaceuticals. Much of their research focuses on neuro-protection. Their website states that:
"The compounds developed by Neuren have application not only to acute brain injuries associated with stroke, cardiopulmonary bypass surgery (CPB) and traumatic brain injury but also in chronic neurological conditions such as Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis".
Their first key drug, Glypromate, is in Phase 2 trials (with the US Army). The company announced today that their second key drug is going into Phase 1 trials.